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Summary
Specific binding sites forhuman pancreatic secretory trypsin inhibitor (PSTI) on 3T3 Swiss albino
cells were studied using radioiodinated recombinant PSTI . Some ion species, pH, and temperature
significantly influenced the binding of 1251-PSTI . Kinetic studies showed that the binding of
1251-PSTI to 3T3 Swiss albino cells reached the maximum level within 120 min at 4°C, with
a slow dissociation rate. The half-maximal inhibition (ID5o ) of 1251-PSTI binding by unlabeled
PSTI occurred at 1.0 x 10 -1oM . On Scatchard analysis of the competitive binding data, linear
plots indicated a single class of receptors with high affinity (Kd = 5.3 x 10 -1o M) on 3T3
Swiss albino cells, the number of receptors being 5,400 per cell . Treatment of surface-bound
radiolabeled PSTI with a chemical crosslinker (disuccinimidyl suberate) led to the identification
of a membrane polypeptide ofMr 140,000 to which PSTI was crosslinked . The formation was
inhibited by an excess amount of unlabeled PSTI in a dose-dependent manner. The binding of
1251-PSTI to 3T3 Swiss albino cells was competitively inhibited by unlabeled PSTI but not by
other peptide hormones, such as epidermal growth factor (EGF), bovine fibroblast growth factor,
insulin-like growth factor, transforming growth factor a, platelet-derived growth factor, and
tumor necrosis factor, indicating the presence of receptors specific for PSTI . Various protease
inhibitors had no or only a little effect, and mercaptoethanol and dithiothreitol strongly decreased
the binding of 1251-PSTI . Incubation at 37°C resulted in rapid internalization of cell-bound
1251_
PSTI, followed by the appearance of trichloroacetic acid-soluble 1251-radioactivity in the culture
medium, due to degradation of internalized PSTI . In addition, PSTI stimulated [3H]thymidine
incorporation intoDNA on 3T3 Swiss albino cells in a dose-dependent manner. The combined
addition of PSTI and EGF stimulated [3H]thymidine incorporation to an extent greater than
that seen with either agent alone . These results indicated that the biological effect of PSTI was
mediated by high affinity plasma membrane receptors, which were not a cell-surface proteinase(s) .
Specific binding of 1251-PSTI was noted with the following cells : WI-38, 3T3 Swiss albino,
HUVE, BDC-1, and H4-II-E-C3 .
Pancreatic secretory trypsin inhibitor (PSTI), 1 first isolated
by Kazal et al . (1), is a specific trypsin inhibitor in pan-
creaticjuice. The physiological role of PSTI has been consid-
ered to be prevention of trypsin-catalyzed premature activa-
tion of zymogens in the pancreas and pancreatic duct (2) .
Recently, we demonstrated that various cancer tissues and
most adenocarcinoma-derived cell lines expressed PSTI, and
that the structure ofPSTIcDNA expressed in neoplastic tissues
was completely identical with that of pancreaticPSTI cDNA
(3) . Furthermore, we reported that serum PSTI was frequently
1 Abbreviations used in this paper: DME/F-12, Dulbecco's modified Eagle's
medium and Ham's F-12 ; EGF, epidermal growth factor; PN, protease-
nexin ; PSTI, pancreatic secretory trypsin inhibitor; Th, thrombin.
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elevated in patients with various malignancies (4, 5) and that
the change in serum PSTI was significantly correlated with
those in acute-phase reactants in serum (6, 7) .
Previously, Hunt et al . (8) and Scheving (9) reported that
the amino acid sequence of PSTI was similar to that of
epidermal growth factor (EGF) . PSTI consists of 56 amino
acids with a molecular mass of 6,242 daltons . EGF is a poly-
peptide hormone comprising 53 amino acids, and stimulates
the growth of a variety of cell types in culture as well as the
growth and differentiation of certain tissues in vivo (10, 11) .
The effects ofEGF were shown to be mediated by a specific
binding protein for EGF on the cell surface (12) and thisEGF-
binding protein was reported to be capable of autodigestion
(13), and EGF also showed trypsin inhibitory activity (14) .
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quences of human PSTI mRNA and murine EGF mRNA
(15) . The sequence homology of PSTI and EGF suggested
the possibility that the functions of PSTI and EGF also
resemble each other. In 1985, we demonstrated that human
PSTI stimulated [3H]thymidine incorporation into DNA
of human fibroblasts at a concentration present in human
serum (16) .
McKeehan et al. reported in 1986 (14) that the first 25
NHZ-terminal amino acid residues of the endothelial cell
growth factor, purified from themedium of a human hepatic
cancer cell line, were identical with those ofhuman PSTI .
The endothelial cell growth factor they reported had a mo-
lecular mass of 6,500 daltons, which is similar to that ofPSTI,
and its amino acid composition was also very similar to that
of PSTI . In the same year, Fukuoka et al . (17) reported that
the 6,500-dalton peptide purified from rat pancreatic juice
stimulatedDNA synthesis in 3T3 Swiss albino cells and the
cell number was also increased after 24-48 h of incubation
with 10-100ng/ml of the peptide. This peptide was consid-
ered to be acholecystokinin-releasing factor andto stimulate
pancreatic enzyme secretion in response to food intake. Later,
theamino acid sequence of thepeptidewas determined (18),
and it wasfound to be identical to that ofrat PSTI-I we purified
(19) . Also, we preliminarily reported that PSTI bound
specifically to various cultured cells, thebinding sites for PSTI
being distinct from thereceptors for EGF (20) . These results
suggested the possibility that, as in the cases of other poly-
peptide hormones, the growth stimulatory action of PSTI
was mediated by a specific plasma membrane receptor pro-
tein . Thus, the identification and characterization of this pro-
tein were carried out using 3T3 Swiss albino cells to clarify
the biological function of PSTI .
Materials and Methods
Cell Lines and Medium.
￿
3T3 Swiss albino cells (mouse fibro-
blast), WI-38 (human lung fibroblast), MIAPaCa-2 (human pan-
creatic cancer), CAPAN-1 (human pancreatic adenocarcinoma), and
H4-II-E-C3 (rat hepatoma)were obtained from theAmerican Type
Culture Collection (Rockville, MD). HuH-6 (human hepato-
blastoma) was obtained from the Japanese Cancer Research Re-
sourcesBank (Tokyo, Japan) . BDC-1 (human bile duct carcinoma)
andGAC-1 (gastric carcinoma) were established in our laboratory.
Human umbilical vein endothelial cells (Endocell) were obtained
from SankoJunyakuCo. (Tokyo, Japan) and maintained inE-GM-
UV (Kurabo Co., Osaka, Japan) . All other cell lines were main-
tained in a 1:1 mixture ofDMEandHam's F-12 (DME/F-12) (Sigma
Chemical Co., St . Louis, MO), supplemented with10% FCS(Gibco
Laboratories, Grand Island, NY), penicillin (100 U/ml), and strep-
tomycin (100 Fcg/ml) . For thebinding studies, 2 x 101 cells were
seeded into 25-cm1 tissue culture flasks (Corning Glass Works,
Corning, NY). The cultures were continued until the monolayers
became confluent (3-4 d after seeding) . Cells were propagated in
a high humidity incubator at 37°C under an atmosphere of5%
C01 and 95% air. The culture medium was routinely changed
every thirdday . Cell lines that grow adherently were harvested by
scraping without prior trypsin treatment to avoid the possible loss
of PSTI receptors due to proteolytic degradation . In some cases
brief EDTA treatment was needed to facilitate detachment . The
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cell number was determined with a hemocytometer and cell via-
bility as determined by the trypan blue exclusion test was over90%.
Growth Factors and Reagents. EGF (human urine), fibroblast
growth factor (b-FGF; bovine brain pituitary extract), insulin-
like growth factor-I (IGF-I ; human recombinant) and platelet-
derived growth factor(PDGF ; porcine platelet) were obtained from
Toyobo Co . (Osaka, Japan) . Human recombinant TGF-a was ob-
tained fromCosmoCo. (Tokyo, Japan) . Human recombinant TNF
was obtained from Suntory Co. (Kyoto, Japan) . Soybean trypsin
inhibitor (SBTI), PMSF, iodoacetate, EDTA, o-phenanthroline,
2-ME, DTT, disuccinimidyl suberate (DSS), lactoperoxidase, and
BSA (7.5% solution) were obtained from Sigma Chemical Co . (St .
Louis, MO). Carrier-free Na-"I was obtained from Amersham
Japan (Tokyo, Japan) . fH]Thymidine (20 Ci/mmol) was from
New England Nuclear (Boston, MA) . Highly purified aprotinin
was kindly supplied by Bayer Co . (Munich, FRG) . Penicillin, strep-
tomycin, sodium bicarbonate (7.5% solution), andPBS tablets (Dul-
becco's formula) were obtained from Flow Laboratories (Irvine, Scot-
land) . An electrophoresis calibration kit for molecular weight
proteins was obtained from Pharmacia Fine Chemicals (Uppsala,
Sweden).Other chemicals used in this studywere ofanalytical grade.
Radioactive Iodination ofHumanPSTI .
￿
RecombinantPSTI was
prepared by expressing a cDNA for PSTI (15), and was supplied
by Shionogi Pharmaceutical Co . (Osaka, Japan) . PSTI was radio-
iodinated with carrier-free Na-"'I by the lactoperoxidase method
(21) with some modifications. Briefly, 5 ,ug of recombinant PSTI
was placed in a conical microvial and then dissolved in 20 pl of
0.05M sodium bicarbonate . Tris-HCI buffer (20 ul each of 0.05
M and 0.5 M, pH 7.4), 1 mCi of carrier-free Na-1151, and 5 Rg
of lactoperoxidase were added to the iodination vial . The iodina-
tion reaction was initiatedby the addition of 5 pl of H101 diluted
1:75,000. After 2 min, the reaction mixture was applied on a
Sephadex G-25 column (PD-10 column ; Pharmacia Fine Chem-
icals, Uppsala, Sweden), which was equilibrated and eluted with
0.05 M Tris-HCI, pH 7.4 . 1151-PSTI obtained from this column
was diluted with DME/F-12 containing 0.2% (wt/vol) BSA and
0.025 M Hepes, pH 7.4 (binding medium), filter-sterilized, and
then stored at 0°C . More than 90% of the radiolabeled peptide
was precipitated by 10% TCA. Radioactivity was measured for
1 min with an automatic gamma counter (Micromedic 4/600;
Rohm and Haas Co., Horsham, PA), with a counting efficiency
of 73%. PSTI was radiolabeled to a specific activity in the range
of 70-100 gCi/,ug.
125I-PSTI Binding Assay.
￿
Binding studies were performed with
confluent monolayers of 3T3 Swiss albino cells in 24-well plastic
plates (BectonDickinson andCo ., Lincoln Park, NJ), as previously
described (22) with some modifications. Cells were seeded at the
density of 1 x 105 cells/well in 1 ml of culture medium and then
grown to confluency. The binding reaction was carried out in 1
ml of binding medium . Kinetic studies on binding at 4, 25, and
37°C were first performed . For all subsequent experiments the
steady-state binding conditions of2hat 4°C were used for further
characterization of the receptors. The cells were incubated in 1 ml
of binding medium with 1151-PSTI (25,000 cpm) and for binding
inhibition studies the indicated amounts ofunlabeled peptides were
added to duplicate or triplicate cultures . Specific binding was defined
as the difference between total binding and nonspecific binding in
the presence of a 200-fold excess amount of unlabeled peptides,
and was always <30% of the total cell bound radioactivity. After
incubation for 2 h at4°C the plates were drained andthen flooded
two times with ice-cold 0.05 M Tris-HCI buffer, pH 7.4, to re-
move any unbound peptides . The cells were then dissolved in 1
ml of0.5NNaOH for 20 min at room temperature and the amountof radioactivitywas determined . For association kinetic experiments,
incubation wells containing either 'III-PSTI alone or "'I-PSTI and
excess unlabeled PSTI were prepared . At the start of the reaction,
the preparation was added to the wells . At various times, superna-
tants were removed. Bound and free 1ISI-PSTI were separated as
described above. For dissociation kinetic experiments, cells were
incubated in the presence of 1 ml of binding medium containing
IIII-PSTI at 4°C for 2 h. After discarding the binding medium,
the cells were washed with ice-cold 0.05 M Tris-HCI buffer, pH
7.4, and then added to either 1 ml of binding medium alone or
1 ml of binding medium containing 3.3 x 10-6 M unlabeled
PSTI . Each experimental point represented the average of dupli-
cate or triplicatedeterminations. Binding data obtained under steady-
state conditions were analyzed using sums of simple Michaelis-
Menten terms as described (23) . Kinetic data were analyzed using
functions that aresums ofexponential terms, as described elsewhere
(24) . Inhibition data were analyzed using an equation for competi-
tive inhibition between two ligands for one type of site (25) .
Scatchard analysis (26) wasperformed to calculate the dissociation
constant and the number of binding sites per cell .
Affinity Crosslinking of 'z51-PSTI to 3T3 Swiss Albino Cells.
Crosslinking experiments were performed with essentially the
method described earlier (27) . 3T3 Swiss albino cells were grown
to confluence in 24-well plastic plates in DME/F-12 containing 10%
(vol/wt) FCS. 1-2 d before ligand binding, the cell culturemedium
wasremoved and replaced with prewarmed DME/F-12 containing
0.5% FCS. The cells were incubated in 1 ml of binding medium
containing 1151-PSTI (25,000 cpm), and the binding reaction was
terminated by washing the monolayer twice with binding medium
andonce with 0.05M PBS, pH 7.5 . The cells were incubated for
20 min at 4°C in the presence of 1 ml of PBS containing 0.3 mM
DSS. The DSS solution was prepared as a 0.03M stock inDMSO
immediately before a crosslinking study. At theendofthis incuba-
tion, the reaction was terminated by the addition of 20 Ed of 2M
Tris-11C], pH 8.0 . After discarding the buffer, the cells were sus-
pended in 100Al of0.05MTris-110, pH 7.5, containing 0.001M
EDTA, 1 x 10-4 M PMSF, 0.2 M NaCl, and 1.0% (wt/vol)
Triton X-100 (extraction buffer) . The cells were incubated in the
extraction buffer for 20 min at 4°C . Insoluble materials were re-
moved by centrifugation at 15,000g for 10 min at 4°C. The super-
natant was analyzed immediately by electrophoresis . Thecompeti-
tion study of "II-PSTI binding with other growth factors, such
as EGF, b-FGF, IGF-I, and TGF-cY, was examined in a similar
manner. All growth factors were used in the PSTI crosslinking
experiment as competitors at the concentration of 1.0 x 10-1M.
SDS-PAGE.
￿
SDS-PAGE was performed essentially as described
by Laemmli (28) . Briefly, all samples were boiled for3min in SDS
sample buffer (0.06MTris-HCI,pH 6.8, containing2%SDS,10%
glycerol, and 5% 2-ME) and then subjected to electrophoresis on
SDS-PAGEPLATE4/20 gradient gel (Daiichi Pure ChemicalsCo.,
Tokyo, Japan) . The molecular weights were determined using the
following standards; myosin (200,000), /j-galactosidase (116,250),
phosphorylase b (92,500), bovine serum albumin (67,000), oval-
bumin (43,000), and carbonic anhydrase (30,000) . After electropho-
resis, the gels were stained with Coomassie blue (0.25% in 25%
isopropanol and 10% acetic acid), dried, and then exposed to Kodak
X-omat AR film (Eastman Kodak, Rochester, NY), with an in-
tensifying screen, at -70°C for 4-7 d .
Internalization and Degradation ofCell BoundPSTI.
￿
The inter-
nalization and degradation of PSTI were estimatedby aprocedure
similar to that describedby Costlow andHample (29) . Aconfluent
monolayer of 3T3 Swiss albino cells was incubated with 1III-PSTI
at 4°C for 2 h on a 24-well plastic plate . The cells were washed
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three times with ice-cold DME/F-12 containing 10% FCS, and
then shifted to 37°C with prewarmed binding medium and fur-
ther incubated at 37°C. At the times indicated, the culturemedium
was harvested, and the cells were washed once with ice-cold PBS
andthen incubated for 5 min at 4°C with 1 ml of0.05M glycine-
HCl buffer, pH 3.0, containing 0.15 M NaCl. After removal of
the glycine buffer, the cells were washed twicewith ice-cold binding
medium and then solubilized in 0.5 NNaOH. The radioactivity
found in the glycine buffer represented surface-bound PSTI, and
that found in solubilized cells represented the internalized PSTI .
To quantitate the degradation of internalized PSTI in cells, TCA
was added to a final concentration of 10% (vol/wt), to culture
medium collected before determination of cell-bound PSTI . The
soluble counts were determined after removal ofthe precipitate by
centrifugation at 3,000 g for 20 min .
rH]Thymidine Incorporation Assay.
￿
Cells were plated into 24-
well plastic plates at 1 x 105 cells/well and then allowed to grow
to confluence in 1 ml of DME/F-12 containing 10% FCS . The
confluent cultures were then shifted to serum-free DME/F-12 con-
taining 0.1% BSA for 48 h before the assay . The cells were in-
cubated with PSTI and/orEGF for 24 h and then [3H]thymidine
(0.2 PCi/ml) incorporation was allowed for 2 h . Theculturewas
washed twicewith ice-cold PBS, and precipitated with ice-cold 10%
TCA. The precipitate was solubilized with 500 pl of 1NNaOH
and then placed in a liquid scintillation vial (Wheaton Scientific,
Milliville, NJ) . An aliquot ofthe solubilized materialswas neutral-
ized by the addition of , 100 Al of 6 N HCl. ['H]Thymidine
incorporated into TCA-insoluble fractions containing 9 ml of
AQUASOL2 (New England Nuclear, Boston, MA) was assayed
with a liquid scintillation counter (Mark III Liquid Scintillation
System, model 6880 ; Searle Analytic, Des Plaines, IL).
Results
Characteristics ofBinding of 125I-PSTI on 3T3 Swiss Albino
Cells. As our preliminary experiments revealed that 3T3
Swiss albino cells bound the highest amount of 1251-PSTI
(20), the optimal conditions for cell binding of 1251-PSTI
were initially determined using3T3 Swiss albino cells as model
cells. Specific binding of 1251-PSTI to 3T3 Swiss albino cells
was time and temperature dependent (Fig. 1) . At 37°C, a
steady state was rapidly attained within 30 min, whereas at
4°C the rate of association was much slower. However, the
binding at 4°C increasedover 2 h, after which time the specific
binding was higher than that obtained for 30 min at 37°C .
On continued incubation for 4 h at 37°C, the amount of
radioactivity that remained bound to the cells decreased to
one-third themaximal value. Considering this result, the stan-
dard experimental condition of 120minofincubation at4°C
was used throughout the study.
Fig. 2 shows the dissociation of 1251-PSTI from its binding
sites on 3T3 Swiss albino cells. This experiment was per-
formed as originally describedby Demeyts et al . (30) to de-
termine whether or not the PSTI receptor exhibited any
cooperative properties .A complex kinetic patternwas revealed,
characterized by fast and slowly dissociating components,
similar to that observed for a number of receptor systems
(31) . The dissociation rate constants obtained in this experi-
ment were 2.1 ± 0.8 x 10+'/min in medium alone and 1.7
± 0.9 x 10 -2 min-1 in the presence of excess unlabeledE
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Figures 1 .
￿
Kinetics of 1 251-PSTI binding at 4°C ([I), 25°C (0), and
37°C (") with 3T3 Swiss albino cells. For each point, 8 x 105 cells were
incubated in a final volume of 1.0 ml of binding medium at the indicated
temperatures with 25,000 cpm 1251-PSTI (2.0 x 10- 9 M) in the presence
or absence of a 1,000-fold excess of unlabeled PSTI . Specific binding was
calculated as describedunder Materials and Methods. Each value represents
the mean for duplicate determinations.
PSTI, while in both cases the rate constant of the slow com-
ponent was <10-2/min . A comparison of the dissociation
of 1251-PSTI from the cells in medium alone, when only a
fraction of the receptors are occupied, with that in the pres-
ence of 3.3 x 10 -6M unlabeled PSTI, when almost all the
receptors are occupied, reveals that the rate of dissociation
Figure 2 .
￿
Dissociation of PSTI from its binding sites on 3T3 Swiss al-
bino cells at 4°C. 8 x 10 5 cells were preincubated with 1 251-PSTI (2 .0
x 10-9 M) for 2 h at 4°C . After discarding the binding medium, the
cells were incubated in either binding medium alone (" ) or binding medium
containing a 1,000-fold excess ofunlabeled PSTI (,&). The cells weremain-
tained at 4°C and the bound radioactivity was measured at the indicated
times . Each point represents the meanofduplicate measurements . Specific
binding was calculated as described in Fig. 1 .
O
0
120
100 -
80 -a
40 -
20
0
Pancreatic Secretory Trypsin Inhibitor Receptor
3 4 5 6
'T
￿
Y
7 8 9 10
pH
Figure 3 .
￿
pH dependence of 1 2 51-PSTI binding to 3T3 Swiss albino
cells. The pH of the incubation buffer (0.2 M Tris) was adjusted with
6 M HC1 or 10 M NaOH as required. Each pH value is the final one
in the incubation medium . Specific binding was calculated as described
under Materials and Methods. Eachpoint represents the mean ofduplicate
measurements .
of PSTI from its receptor is insensitive by occupancy of adja-
cent receptors . This suggests that PSTI receptors on3T3 Swiss
albino cells are noncooperative .
Fig . 3 shows the binding dependence on pH, from 3.0 to
9.0. The optimal pH for specific binding was 7.4-8.0 .
Table 1 shows the effects of various ions in the incubation
buffer. Cal+ and Mgt + decreased the binding of 1251-PSTI
in a dose-dependent manner and had additive effects, while
the other divalent ions tested had less effect on the binding .
On the other hand, monovalent cations such as Na+ and
K+ had no effect at all on the binding at the concentration
of 0.1 M .
Specificity ofPSTI Binding.
￿
Fig . 4 shows the inhibition
of binding of 1251-PSTI to 3T3 Swiss albino cells by unla-
beled PSTI . Binding of 1251-PSTI to the cells was competi-
tively inhibited by increasing concentrations of unlabeled PSTI,
from 1.0 x 10-11 M to 3 .0 x 10_8 M . The half-maximal
inhibition (IDS0) of the PSTI binding occurred at 1.0 x
10 -1o M .
Fig. 5 shows a Scatchard plot of the binding data presented
in Fig . 4 . Scatchard analysis suggested that 3T3 Swiss albino
cells had a single binding site with an apparent dissociation
constant (Kd) of 5.3 x 10-10 M, with the estimated number
of binding sites for PSTI being 5,400 per cell .The effects of various cation species on 1251-PSTI binding to 3T3 Swiss
albino cells were examined . Cells were incubated with 25,000 cpm
1251-PSTI for 2 h at 4°C in the presence of various cation species .
Values are expressed as percentages of the control level .
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￿
Inhibition of 1251-PSTI binding to 3T3 Swiss albino cells by
unlabeled PSTI . Cells were incubated with 25,000 cpm 1251-PSTI for 2 h
at 4°C in the presence of increasing concentrations of unlabeled PSTI .
Thebinding datawereanalyzed as described under Materials and Methods.
Each point represents the mean of duplicate measurements.
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Scatchard plot of binding data presented in Fig. 4 .
The specificity of 1251-PSTI binding was investigated by
examining the capacity of other growth factors and cytokines
in comparison to unlabeled PSTI to compete with 1251-PSTI
binding. Only PSTI could compete with 1251-PSTI binding,
the other growth factors not doing so (Fig . 6) . This sug-
gested, at least for 3T3 Swiss albino cells, that the receptor
to which PSTI binds was specific for this peptide .
Affinity Crosslinking of 1251-PSTI to 3T3 Swiss Albino
Cells . To study the structure of the binding site for 125I-
PSTI on 3T3 Swiss albino cells, 1251-PSTI was chemically
crosslinked to cell monolayers through the homofunctional
reagent, DSS. When 0.3 mM DSS was used as a crosslinker,
1251-PSTI was found to be associated with a macromolecular
complex ofM 140,000 (Fig. 7) . Excess unlabeled PSTI
effectively competed with 1251-PSTI binding in a dose-
dependent manner. However, excess unlabeled human EGF,
b-FGF, and IGF-I did not compete with 1251-PSTI for
binding or crosslinking to the apparentM 140,000 species.
Internalization and Degradation ofBound 1257-PSTI .
￿
Inter-
nalization and subsequent degradation are common conse-
quences of peptide hormone-receptor interaction (32) . As
shown for other protein ligands, elution of cell surface-bound
PSTI was markedly pH dependent . Cell-bound 1251-PSTI be-
came resistant to release withpH 3.0 buffer after 1 h at 37°C,
which indicated that receptor-bound PSTI had been inter-
nalized by the cells. The early increase in intracellular radio-
Table 1 . Effects of Various Ion Species on 12'I-PSTI Binding 0 .0'21C
Specific binding
Ion Concentration of "'I-PSTI
MM
Control - 100" 0.015
Na' 100 102
10 100
K+ 100 97 N
10 99 L
Ca21 10 49 0.010
5 50
2 89 C
Mg2+ 10 63
O 5 82 m
2 98 0 .005
Mn2 + 10 101
1 100
Nit+ 10 100
1 102
Zn2 + 10 90 0.000
1 99
Ca21 + Mg2+ 10 + 10 26
5+5 38
2+2 8330
20
10
0
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Figure 6.
￿
Specificity of 1251-PSTI binding to 3T3 Swiss albino cells.
Cells (8 x 105 cells/well) were incubated with 125I-PSTI (2 .0 x 10 -9
M) and the following unlabeled peptides, at the concentrations indicated:
(A) none ; (B) recombinant human PSTI, 3 .3 x 10-6M; (C) recombinant
human EGF, 3.3 x 10-6 M; (D) recombinant human TGF., 3.6 x 10 -6
M ; (E) bovine b-FGF, 1.5 x 10 -6 M ; (F) porcine platelet PDGF, 1.2 x
10-6 M; (G) recombinant human IGF-1, 2.6 x 10-6 M ; (M recombinant
human TNF, 1.2 x 10-6 M; and (1) aprotinin, 3.3 x 10 -6 . Incubation
was performed for 2 h at 4°C and binding was assayed as described under
Materials and Methods. Values are means ± SD for three experiments.
activity was followed by a gradual decrease. 121 1 radioactivity
was first detected in themedium after 1 or 2 h and continued
to increase until 6 h . These results suggested that internali-
zation and subsequent degradation of 1251-PSTI occurred
after binding to specific receptors at 37°C (Fig . 8) .
Effects of Various Agents on Specific Binding of '2 I-PSTL
The effects of various protease inhibitors and chemical re-
agents on 1251-PSTI binding were investigated (Table 2) .
Treatment of 3T3 Swiss albino cells with o-phenanthroline
resulted in a little loss of binding activity, whereas other pro-
tease inhibitors had no or only a little effect on the binding
activity of 1251-PSTI . 2-ME and DTT strongly decreased the
binding activity toward 1251-PSTI .
Stimulation ofDNA Synthesis by PSTI .
￿
The time course
ofDNA synthesis, monitored as the incorporation oflabeled
thymidine, following the addition of PSTI to confluent and
quiescent 3T3 Swiss albino cells is shown in Fig . 9 . Under
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Figure 7 .
￿
Characterization of PSTI receptor by affinity crosslinking.
Cells (1 x 107 cells/ml) were incubated with 1251-PSTI in the absence of
unlabeled PSTI (lane 2), or in the presence of increasing concentrations
of unlabeled PSTI (1.0 x 10-10 , 1 .0 x 10 -9 M, and 1.0 x 10-8M in
lanes 3, 4, and 5, respectively), 1251-PSTI only (25,000 cpm; lane 1), EGF
(1.0 x 10-6 M ; lane 6), b-FGF (1 .0 x 10-6 M ; lane 7), or IGF-I (1 .0
x 10-6M; lane 8) . 125I-PSTI was crosslinked to the cells with 0 .3 mM
DSS and then analyzed by 4/20 gradient SIDS PAGE . The arrow indicates
the PSTI-receptor complex ofM 140,000. The autoradiogram was ob-
tained as described under Materials and Methods.
these experimental conditions, an increased rate ofDNA syn-
thesis was detectable after 12 h incubation in the presence
of 100 ng/ml PSTI . The maximal stimulation was observed
at -30 h . The stimulatory effects of increasing concentra-
tions of PSTI and EGF on DNA synthesis are presented in
Table 3 . [3H]Thymidine incorporation was dependent on the
concentration ofPSTI . This pattern of thymidine incorpora-
tion stimulation by PSTI was similar to those observed for
EGF. Moreover, the combined addition of PSTI and EGF
stimulated [ 3H]thymidine incorporation to an extent greater
than that seen with either agent alone.
Speck Binding of1251-PSTI to Various Cultured Cells.
￿
The
capacity of a variety of cell lines to bind 1211-PSTI was ex-
amined (Table 4) . No appreciable specific binding of
1251_
PSTI was detected with the following cultured cells : MIA
PaCa-2, CAPAN-1, HuH-6, andGAC-1 . Specific binding of
1211-PSTI was noted with the following cells : WI-38, 3T3
Swiss albino, HUVE, BDC-1, and H4-II-E-C3 . These results
indicated that some, but not all, cultured cells derived from
a number of species (human, mouse, and rat) were capable
of binding human PSTI .
Discussion
The present study demonstrated rapid, specific, and revers-
ible binding of radioactive iodinated human PSTI to3T3 SwissN
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Figure 8 .
￿
Internalization and degradation of 1251-PSTI bound to 3T3
Swiss albino cells. Surface bound (A), internalized (" ), and degraded (p)
1251-PSTI . 1251-PSTI was determined as described under Materials and
Methods . Each point represents the mean of duplicate measurements .
albino cells . The maximal binding was observed at 4°C, in-
dicating that the binding site was stable under the condi-
tions used . On the other hand, incubation at 4°C resulted
in minimal label degradation of 1251-PSTI, which permitted
high specific binding (Fig. 1) .
Divalent cations are known to cause specific binding to
other polypeptide hormone receptors (33, 34) . The present
study showed that monovalent cations had no effect at physi-
ological concentrations on the specific binding of 1251-PSTI,
whereas Cat+ and Mgt+ decreased the specific binding
(Table 1) . Divalent cations such as Cat+ and Mgt+ could
alter the conformation of PSTI and/or the binding site or
might alter the electrostatic interaction between them . Treat-
ment with 2-ME and DTT resulted in a significant loss of
binding activity (Table 2), indicating that intrachain disulfide
bonds might be of some importance for the binding ofPSTI
to cells.
Scatchard analysis suggested that 3T3 Swiss albino cells
had a single high affinity binding site for PSTI, with a Kd
of 5.3 x 10 -10 M, and that there were 5,400 sites per cell .
In addition, Fig . 2 indicated that the binding was reversible
and PSTI receptors were noncooperative. Thus, PSTI has high
affinity and low capacity binding sites on 3T3 Swiss albino
cells . In order to identify the high affinity PSTI binding do-
main present on the surface of3T3 Swiss albino cells, experi-
ments involving crosslinking to a polypeptide present on the
cell surface associated with PSTI were performed . An intense
band at a position corresponding to 140,000 daltons was ob-
served on the SDS-PAGE auto-radiogram . As this band dis-
appeared completely with excess unlabeled PSTI, we con-
cluded that the 140,000 dalton band represented a PSTI-PSTI
receptor complex. Human EGF, b-FGF, and IGF-I did not
cause the disappearance of this band .
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Table 2 .
￿
Effects of Various Agents on Specific Binding
of -'I-PSTI
Cells (2 x 105/ml) were preincubated with various protease inhibitors
or chemical reagents for 10 min at room temperature . The treated cells
were then centrifuged at 15,000 g for 10 min and the pellets were
resuspended in the binding buffer . The binding activity was determined
after this resuspension . Cells that had not been exposed to reagents or
enzymes but incubated in the same manner and centrifuged for the same
period were used as a control.
` Values are expressed as percentages of the control level and means of
duplicate determinations .
After internalization, intracellular degradation of PSTI could
be demonstrated (Fig . 8) . Our results indicated that receptor-
mediated endocytosis and intracellular degradation occurred
after PSTI binding to cell surface receptors . Thisphenomenon
was also observed for a protease-nexin (PN), known as a serine
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Figure 9 .
￿
Time course of [3H]thymidine incorporation after stimula-
tion of3T3 Swiss albino cells . Confluent, quiescent cultures of cells were
stimulated by the addition of 100 ng/ml PSTI (") . Nothing was added
to control cultures (A) .
Treatment Concentration
Percent of
control`
None 100
Soybean trypsin inhibitor 50 ug/ml 98
PMSF 5 x 10-3 M 89
Leupeptin 5 x 10-3 M 90
lodoacetate 5 x 10-3 M 96
p-Chloromercuribenzoate 5 x 10-3 M 76
EDTA 5 x 10-3 M 91
o-Phenanthroline 5 x 10-3 M 86
Mercaptoethanol 1 x 10-3 M 50
5 x 10-3 M 34
Dithiothreitol 1 x 10-3 M 32
5 x 10-3 M 20The stimulation of thymidine incorporation by PSTI and EGF was examined . Varying concentrations of PSTI with or without EGF were added
to the cells . 24 h later, [3H]thymidine was added and the cells were labeled for 2 h .
Values are means ± SD for three experiments .
Table 4.
￿
Binding of 125I-PSTI to Various Cultured Cells
protease inhibitor . Low et al . (35) reported that PN, a com-
ponent released by normal human fibroblasts into the cul-
ture medium, formed covalent linkages with thrombin (Th) .
After the Th-PN complexes bound to fibroblast cells, they
were rapidly internalized and degraded .
PSTI was originally isolated as a trypsin inhibitor, so it
might be thought that the specific binding sites for PSTI
arethe cell-surface proteinase(s) . Our present resultsdemon-
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The binding of 1251-PSTI to various cultured cells was examined . The binding data were analyzed as described under Materials and Methods . Values
are means for duplicate determinations .
strated that pretreatment of3T3 Swissalbino cellswith var-
ious protease inhibitor had no effect on the specific binding
of 1251-PSTI (Table 2), and that aprotinin, a bovine pan-
creatic trypsin inhibitor, also did not competewith 1251-PSTI
binding. In a separate experiment, we observed that the ad-
dition oftheexcessamount of various protease inhibitors did
not inhibit the binding of PSTI to 3T3 Swiss albino cells
(data not shown) . Therefore, the binding sites for PSTI can
Trypsin Inhibitor Receptor
Table 3. Stimulation of3T3 Swiss Albino Cells by PSTI and EGF
[3H]Thymidine incorporation
Factors Final concentration cpm/well Percent of control
None 412.2 ± 15.4' 100
PSTI 1 ng/ml 721 .4 ± 110.2 180
5 ng/ml 1,480.2 ± 131 .5 360
10 ng/ml 1,883.8 ± 163.5 460
EGF 1 ng/ml 1,051 .0 ± 91.2 260
5 ng/ml 1,897.2 ± 90.5 460
10 ng/ml 2,412.8 ± 130.0 590
PSTI + EGF 5 + 5 ng/ml 3,241 .4 ± 295 .5 790
10 + 10 ng/ml 4,057.2 ± 279.0 990
SBTI + EGF 5 jug/ml. + 5 ng/ml 2,104.6 ± 154.5 510
FCS 5% 1,692.1 ± 142.5 410
10% 2,455 .9 ± 139.5 600
Cells
Total 1251-PSTI
added to the well Total
Bound 1151-PSTI to 1 x 106 cells
Nonspecific Specific
cpm
WI-38 23;300 2,510 210 2,300
3T3 Swiss albino 22,900 2,830 250 2,580
HUVE 23,900 1,620 340 1,280
MIA PaCa-2 24,400 640 450 190
CAPAN-1 24,700 830 620 210
BDC-1 23,900 920 200 720
HuH-6 23,800 1,550 620 930
GAC-1 24,000 1,260 1,080 180
1-14-11-E-0 25,100 1,600 540 1,060be different from the cell-surface proteinase, though a possi-
bility still remains . PSTI itself stimulated DNA incorpora-
tion into 3T3 Swiss albino cells in a dose-dependent manner,
as shown in Table 3, and the pattern resembled that in the
case ofEGF. The combined addition ofPSTI andEGF stimu-
lated [3H]thymidine incorporation to an extent greater than
that seen with either peptide alone. These findings, together
with the results reported by Fukuoka et al . (17), raise the
possibility that PSTI could be a growth-stimulating factor.
Scott and Scow reported that, despite having investigated
a wide range of concentrations of protease inhibitors, such
as a1-protease inhibitor and bovine pancreatic trypsin inhib-
itor, no evidence was found of mitogenic or growth stimula-
tory activity (36) . Although the mitogenic effects of pro-
teases on cells in monolayers have been documented (37-40),
few studies have examined the potential role of protease in-
hibitors as mitogens . However, four lines ofevidence, recently
provided, indicated that protease inhibitors can be mitogenic:
(a) McKeehan et al . (14) have established that PSTI and uri-
nary glycoprotein protease inhibitor, which are both serine
protease inhibitors produced in significant quantities by HepG2
cells, do stimulate the growth ofhuman endothelial cells in
a serum-free monolayer culture ; (b) TGF-0 has been shown
to induce the production ofa metalloproteinase inhibitor that
is thought to facilitate anchorage-independent growth by in-
hibiting extracellular matrix degradation (41) ; (c) Cook and
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